Partnering, licensing, and collaboration are essential to our business and the end-goal of all our commercialization efforts. We depend on these activities to create lasting and growing value from our proven innovation. To this end Micropharma has focused significant resources to build a team, process, and company to make these relationships successful.
Micropharma is always interested in building new relationships, growing existing ones, and working with interested, qualified investors who would like be part of our growing company.
October 22, 2013
Micropharma Limited today announced the completion of a new lab test to quantify bile salt hydrolase (bsh) gene abundance in gut-derived samples. Scientific reports have recently shown that individuals with inflammatory and metabolic ailments including inflammatory bowel disease, irritable bowel syndrome, hypercholesterolemia and type II diabetes present low quantities of bsh gene in their gastrointestinal microbiome. Microbiome SenseIT bsh, the lab test, will serve to provide health care practitioners and patient with additional information regarding the abundance of the gene. Micropharma aims to expand the development of the SenseIT platform which represents the first approach to personalized medicine tests based on microbiome analysis.
August 09, 2013
Micropharma Limited today announced that they have reached an agreement with Atrium Innovations Inc., a world leader in science-based natural health products, to commercialize products to be sold directly to healthcare practitioners. For Micropharma, this agreement provides access to commercialize its technologies in new key markets.